SAN ANTONIO CENTER OF BIOMARKERS OF RISK FOR PROSTATE CANCER (SABOR)

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。前列腺癌是美国男性最常见的癌症。现有的生物标志物-直肠指检（DRE）和PSA -敏感性和特异性较差。来自前列腺癌预防试验和其他研究的数据表明，体质（如家族史、遗传变异）、行为（如体重指数、饮食）以及躯体（如GSTPi甲基化）等因素的结合，可以改善前列腺癌患者和非前列腺癌患者之间的区别。圣安东尼奥前列腺癌风险生物标志物中心（SABOR）是一项基于人群、少数群体和服务不足的队列研究，在追踪癌症相关结果的同时收集广泛的临床数据和生物标本，旨在发现、开发和验证前列腺癌风险的生物标志物。迄今为止，在大约3年的累积时间里，3142名男性被纳入研究，其中51%为西班牙裔或非裔美国人。利用SABOR的整个EDRN CEVC研究成果，我们发现了影响前列腺癌风险的几个因素，包括一些遗传变异（雄激素受体、信号蛋白3B和3F、SRD5A2中的CAG重复长度和维生素D受体的变异）和体重指数（PSA水平越低，数值越高）。我们还发现不同种族的前列腺癌危险因素（热量摄入、脂肪摄入、微量营养素摄入、体重指数、水果和蔬菜摄入）存在显著差异，PSA和DRE在这些种族/种族群体中的表现特征也不同。在SABOR更新中，我们将完成9000名男性的队列招募，进一步探索这些行为、体质和躯体风险因素，开发和验证多变量前列腺癌风险算法，并进行EDRN网络验证研究。SABOR的科研人员将继续在网络中担任领导职务，协助EDRN设计、实施和分析早期检测验证研究，这些研究将改变美国临床实践的护理标准。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Prostate cancer is the most common cancer in U.S. men. Existing biomarkers - digital rectal examination (DRE) and PSA - have poor sensitivity and specificity. Data from the Prostate Cancer Prevention Trial and other studies suggest that a combination of factors - constitutional (e.g., family history, genetic variations), behavioral (e.g., body mass index, diet), as well as somatic (e.g., GSTPi methylation) - can improve the discrimination between men with and without prostate cancer. The San Antonio Center for Biomarkers of Risk of Prostate Cancer (SABOR) is a population-based, minority and underserved-enriched, cohort study that collects extensive clinical data and biospecimens while tracking cancer-related outcomes, designed to discover, develop, and validate biomarkers of prostate cancer risk. To date, 3,142 men have been enrolled over approximately 3 years of accrual including 51% Hispanic or African American subjects. Using the entire EDRN CEVC efforts of SABOR, we have found several factors that affect prostate cancer risk including a number of genetic variations (CAG repeat length in the androgen receptor, Semaphorins 3B and 3F, SRD5A2, and variations of the Vitamin D receptor) and body mass index (higher values associated with lower levels of PSA). We have also found substantial differences in risk factors for prostate cancer in different ethnic groups (caloric intake, fat intake, micronutrient intake, body mass index, fruit and vegetable intake) as well as different performance characteristics of PSA and DRE in these ethnic/racial groups. In the SABOR renewal, we will complete recruitment of 9,000 men in the cohort, explore further these behavioral, constitutional, and somatic risk factors, develop and validate a multivariable prostate cancer risk algorithm, and conduct EDRN Network validation studies. The SABOR scientific personnel will continue to serve in their leadership positions within the Network, assisting the EDRN with the design, conduct, and analysis of early detection validation studies that will alter the standard of care of clinical practice in the United States.